MAPT and Alzheimer disease: Our results are consistent with another clustering work28 in an independent cohort of 151 patients with AD, in which a group with higher levels of Tau and lower amyloid levels was associated with worse clinical outcomes over time, including faster cognitive decline and higher mortality.